iX Biopharma (SGX:42C) Net Change in Cash : S$-3.98 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

iX Biopharma's Net Change in Cash for the six months ended in Dec. 2024 was S$0.37 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was S$-3.98 Mil.

iX Biopharma Net Change in Cash Historical Data

The historical data trend for iX Biopharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Net Change in Cash Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Net Change in Cash

Get a 7-Day Free Trial

-10.24

1.12

7.32

-6.98

-4.77

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															-2.21	-4.77	-0.43	-4.35	0.37

iX Biopharma Net Change in Cash Calculation

iX Biopharma's Net Change in Cash for the fiscal year that ended in Jun. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-6.553	+	1.056	+	0.724	+	0
	=	-4.77

iX Biopharma's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -1.969 + -0.122 + 2.445 + 0.012

= 0.37

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$-3.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iX Biopharma Net Change in Cash Related Terms
Thank you for viewing the detailed overview of iX Biopharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Net Change in Cash

Comparable Companies

SGX:BFK ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines